Premium
Inherited Thrombophilia and IVF Failure: The Impact of Coagulation Disorders On Implantation Process
Author(s) -
Ivanov Petar,
Tsvyatkovska Tsvetomira,
Konova Emiliana,
KomsaPenkova Regina
Publication year - 2012
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/j.1600-0897.2012.01156.x
Subject(s) - trophoblast , endometrium , plasminogen activator , microbiology and biotechnology , coagulation , integrin , embryo , endothelium , andrology , extracellular matrix , biology , immunology , medicine , endocrinology , receptor , placenta , fetus , genetics , pregnancy
In connection with the embryo acceptance process after IVF procedure, endometrial cells surface receptors, extracellular matrix ( ECM ) molecules, endothelium and blood circulation factors were involved in remodelling of endometrium. Plasminogen activator inhibitor type 1 plays a significant role during the early phases of placental vascular remodelling and regulates the trophoblast invasion through controlling plasmin activity. Endometrial cell surface protein integrin alphaV/beta3, responsible for the adhesion of the embryo, has had also the same subunit beta3, which is component of integrin alpha II b/beta3 connected with platelet aggregability. Prothrombin, furthermore, has had a debatable effect upon endothelial and mesenchymal cells and possible contribution on embryo vascular development. Confoundable data have been present about the role of coagulation factor V and its role for implantation. These and other coagulation factors have relatively common gene polymorphisms that enhanced their activity. This review discusses the effect of increased coagulation activity on implantation process, which is not yet fully determined. The establishment of the positive or negative impact of mother hypercoagulability on the success of embryo implantation after assisted reproduction technology could determine the timing of preventing anticoagulant therapy in women with history of early embryo loss.